WebNov 28, 2024 · CinCor Pharma Inc (NASDAQ: CINC) announced topline results and completion of its Phase 2 HALO trial of baxdrostat in patients with uncontrolled hypertension taking up to two blood pressure … http://m.yakup.com/news/index.html?mode=view&pmode=&cat=all&cat2=1&cat3=&nid=277747&num_start=960
CinCor Pharma Announces Pricing of Upsized Public ... - Yahoo …
WebJan 9, 2024 · 6 analysts have issued twelve-month price objectives for CinCor Pharma's stock. Their CINC share price forecasts range from $30.00 to $67.00. On average, they expect the company's stock price to reach $46.67 in the next year. This suggests a possible upside of 60.6% from the stock's current price. View analysts price targets for CINC or … chimbalkar farms and resort
[약업신문]JPM서 다시 증명된 AI 신약개발 …
WebYahoo February 21, 2024. CinCor CEO: acquisition by AstraZeneca was more than a year in the making. Before CinCor Pharma Inc. agreed to a $1.8 billion acquisition by AstraZeneca plc, it turned down several other offers from the U.K. pharmaceutical giant. Yahoo January 26, 2024. Why These Two Biotech Stocks Blasted Higher This Week WebAug 8, 2024 · Conference Call and Webcast Information. CinCor management will hold a conference call and webcast today at 8:30 AM Eastern Time to provide an update on the BrigHtn Phase 2 trial. The dial-in ... WebApr 6, 2024 · Financial Performance. In 2024, AstraZeneca's revenue was $44.35 billion, an increase of 18.53% compared to the previous year's $37.42 billion. Earnings were $3.29 billion, an increase of 2835.71%. Financial Statements. chim bay vector